The gastric balloon is a non-surgical endoscopic weight loss procedure that involves the placement of saline or gas-filled balloon into the stomach to suppress appetite and drastically reduce food intake. The gastric balloon is considered as an alternative to conventional bariatric surgery in obese people.
Patients diagnosed with obesity and with associated health risks such as diabetes and hypertension are given the option to undergo gastric balloon procedure. According to World Health Organization (WHO), during the year 2016, approximately more than 1.9 billion adults, aged over 18 years, were overweight and out of these over 650 million adults were obese and also an approximate 41 million children under the age of 5 years were overweight or obese. Rising prevalence of obesity and increasing demand for minimally invasive surgeries are the key driving factors in the gastric balloons market.
Key Market Trends
Triple Gastric Balloons Segment is Expected to Register Robust Growth Rates During The Forecast Period
Triple gastric balloons system is a non-surgical treatment in which three balloons are placed for optimal weight loss. Obalon balloon is the only FDA approved triple gastric balloon or device which helps in weight loss and it works by taking up space in the stomach. Obalon balloon is delivered into the stomach by swallowing a capsule that is connected to a small bendable tube for six months which is combined with a professionally supervised nutrition and exercise program.
Obesity is a chronic disease characterized by excessive accumulation of adipose tissue in the body which results in adverse health effects and this was responsible for about 4.7 million premature deaths in the year 2017, globally as per World Health Organization (WHO). Hence, the rising prevalence of obesity and increasing demand for minimally invasive surgeries are the key driving factors in the triple gastric balloons segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the global gastric balloon market due to rising prevalence of obesity due to diet and lifestyle changes and preference for minimally invasive technique in this region. According to Organization for Economic Co-operation and Development (OECD), in the year 2017, around 40% of the population is reported to be obese. Furthermore, rise in the adoption of advanced technologies such as gastric balloons and presence of established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The Gastric balloon Market is moderately consolidated, competitive and consists of several emerging market players. In terms of market share, few of the major players are currently dominating the market. Companies are developing novel products, furthermore, mergers and acquisitions are also fostering the technological advancements and operational expansions in the gastric balloon industry. Some of the companies which are currently dominating the market are Obalon Therapeutics, Allurion Technologies, Apollo Endosurgery, Districlass Medical, Helioscopie Medical Implants, Silimed, Lexel, Medsil, ReShape Medical, Spatz.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Obalon Therapeutics, Inc.
- Allurion Technologies
- Apollo Endosurgery, Inc.
- Districlass Medical SA
- Helioscopie Medical Implants
- Silimed, Inc. (Sientra)
- Medsil
- ReShape Medical ( ReShape Lifesciences Inc.)
- Spatz Cosmeceutical Inc.
Methodology
LOADING...
